Medicare Part D: Watch Those Numbers

What happens to the drug benefit depends on how many people enroll. So far, that’s not many.

Fight disinformation: Sign up for the free Mother Jones Daily newsletter and follow the news that matters.


In the short run, what happens to the drug benefit depends critically on enrollment, enrollment, and enrollment. Yet voluntary enrollment in the benefit has been sluggish so far at best.

If beneficiaries enroll steadily despite their confusion, irritation, and the deserved bad publicity for the benefit as it has gone “live,” the market-based design will have a chance to work temporarily—probably until the federal government stops assuming much of the insurers’ risk. Insurers flocked to the benefit in large part because there was some chance that they could make money without much chance of loss. If enrollment is robust, drug companies will compete to offer lower prices, premiums will remain relatively low, plans will stay in the market, and beneficiary dissatisfaction with the program will subside. If enrollment continues to flag, premiums will rise, plans will pull up stakes, and the future of the benefit will be in more immediate jeopardy.

As it stands, due to the complicated design and the ham-handed implementation of the benefit, the rollout seems almost calculated to reap successive waves of bad publicity. First we saw the mystifying two-stage sign-up process for dual eligibles, followed by the announcement of participating drug plans without adequate supporting information, and then the bungled transfer of beneficiaries from Medicaid to Medicare. Another round of negative publicity may predictably ensue in May, when beneficiaries who haven’t yet signed up face late enrollment penalties.

The drug benefit’s implementation has been so feckless that one might think—even making reasonable allowance for bureaucratic snafus—that the success of freestanding drug plans is not the administration’s intent. Instead, it may be pursuing a more longstanding goal—increasing enrollment in private Medicare managed care plans. Compared to negotiating the labyrinth of premiums and cost-sharing arrangements in the standalone prescription drug plans (PDPs), joining a Medicare HMO is a snap.

This migration toward comprehensive private plans might already be in the works. As an article in yesterday’s Wall Street Journal points out, Humana plans to use the lure of low premiums for its PDPs as a loss leader for its more profitable Medicare Advantage (MA) plans. To be sure, this may only be one insurer’s gamble, but the enrollment numbers for MA plans bear watching.

One other enrollment number, sadly, stands out: the relatively low number of low-income Medicare beneficiaries who have successfully applied for subsidies. Just 1.1 million of the 4.6 million HHS projected last year would receive this subsidy in 2006 have been approved thus far. Since these are the beneficiaries who stand to gain the most from the drug benefit, this slow take-up rate is especially troubling.  

WE'LL BE BLUNT:

We need to start raising significantly more in donations from our online community of readers, especially from those who read Mother Jones regularly but have never decided to pitch in because you figured others always will. We also need long-time and new donors, everyone, to keep showing up for us.

In "It's Not a Crisis. This Is the New Normal," we explain, as matter-of-factly as we can, what exactly our finances look like, how brutal it is to sustain quality journalism right now, what makes Mother Jones different than most of the news out there, and why support from readers is the only thing that keeps us going. Despite the challenges, we're optimistic we can increase the share of online readers who decide to donate—starting with hitting an ambitious $300,000 goal in just three weeks to make sure we can finish our fiscal year break-even in the coming months.

Please learn more about how Mother Jones works and our 47-year history of doing nonprofit journalism that you don't find elsewhere—and help us do it with a donation if you can. We've already cut expenses and hitting our online goal is critical right now.

payment methods

WE'LL BE BLUNT

We need to start raising significantly more in donations from our online community of readers, especially from those who read Mother Jones regularly but have never decided to pitch in because you figured others always will. We also need long-time and new donors, everyone, to keep showing up for us.

In "It's Not a Crisis. This Is the New Normal," we explain, as matter-of-factly as we can, what exactly our finances look like, how brutal it is to sustain quality journalism right now, what makes Mother Jones different than most of the news out there, and why support from readers is the only thing that keeps us going. Despite the challenges, we're optimistic we can increase the share of online readers who decide to donate—starting with hitting an ambitious $300,000 goal in just three weeks to make sure we can finish our fiscal year break-even in the coming months.

Please learn more about how Mother Jones works and our 47-year history of doing nonprofit journalism that you don't elsewhere—and help us do it with a donation if you can. We've already cut expenses and hitting our online goal is critical right now.

payment methods

We Recommend

Latest

Sign up for our free newsletter

Subscribe to the Mother Jones Daily to have our top stories delivered directly to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate